• Morgan Stanley analyst sets a new price target for BAX at $15, indicating a potential downside from its current trading price.
• Faruqi & Faruqi, LLP investigates potential claims against Baxter International Inc. for investors who purchased securities between February 23, 2022, and July 30, 2025.
• BAX's current stock price reflects a slight increase, trading at $19.08 with a market capitalization of approximately $9.81 billion.

Baxter International Inc. (NYSE:BAX) is a global healthcare company that provides a broad portfolio of essential medical products, including dialysis equipment, intravenous solutions, and surgical instruments. The company operates in a competitive landscape with peers like Medtronic and Becton Dickinson. On December 2, 2025, Patrick Wood from Morgan Stanley set a new price target for BAX at $15. At that time, the stock was trading at $19.08, indicating a price difference of approximately -21.38% from the target.

Faruqi & Faruqi, LLP, a national securities law firm, is investigating potential claims against Baxter. The focus is on investors who purchased or acquired BAX securities between February 23, 2022, and July 30, 2025. Investors who have suffered losses during this period are encouraged to contact James (Josh) Wilson, a Securities Litigation Partner at the firm, to discuss their legal options. The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Baxter is December 15, 2025.

Currently, BAX is priced at $19.08, reflecting an increase of 1.81% or $0.34. Today, the stock has fluctuated between a low of $18.55 and a high of $19.20. Over the past year, BAX has reached a high of $37.74 and a low of $17.40. The company, listed on the NYSE, has a market capitalization of approximately $9.81 billion. Today's trading volume for BAX is 8,389,032 shares.

The investigation by Faruqi & Faruqi, LLP, adds another layer of complexity to the situation. Investors who have experienced losses during the specified period are encouraged to explore their legal options. The deadline for seeking the role of lead plaintiff in the federal securities class action against Baxter is December 15, 2025.